EE359 US Cost-Effectiveness of Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL), Considering Infusion Setting and Payor Claims Data

Autor:	AK Cummings Joyner, J Snider, S Wade, ST Wang, MG Buessing, S Johnson, U Gergis
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S405
ISSN:	1098-3015
DOI:	10.1016/j.jval.2022.04.607
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3a3bd2fc6ec976c925bc4e4af2435eb0 https://doi.org/10.1016/j.jval.2022.04.607 Zobrazit plný text záznamu Full Text from ScienceDirect